Actions of prednisolone acetate, pregnenolone-16α-carbonitrile, and triamcinolone upon drug resistance and metabolism: a comparative study

1977 ◽  
Vol 55 (3) ◽  
pp. 363-366 ◽  
Author(s):  
P. Kourounakis ◽  
H. Selye
Keyword(s):  
Plasma Concentrations ◽  
The Body ◽  
Female Rats ◽  
Prednisolone Acetate ◽  
Microsomal Enzyme ◽  
Enzyme Inducer ◽  
Drug Metabolizing Enzyme ◽  
Metabolizing Enzyme ◽  
Microsomal Enzyme Induction

In female rats, pretreatment with prednisolone acetate diminished the duration of zoxazolamine-induced paralysis as well as its plasma concentrations and increased significantly the in vitro metabolism of zoxazolamine and ethylmorphine. These actions of prednisolone were compared with those of equimolar amounts of pregnenolone-16α-carbonitrile (PCN) (a known microsomal enzyme inducer) and of triamcinolone (an agent that reduces the sensitivity of the body to drugs although not via microsomal enzyme induction). Prednisolone proved to be a strong drug-metabolizing enzyme inducer but it was less potent than PCN.

Effect of Splenectomy on the Activity of Drug-Metabolizing Enzymes in the Liver of Rats

1971 ◽  
Vol 49 (3) ◽  
pp. 161-166 ◽  
Author(s):  
Jules Brodeur ◽  
Claude Marchand
Keyword(s):  
Indirect Evidence ◽  
Female Rats ◽  
Microsomal Enzymes ◽  
Drug Metabolizing Enzyme ◽  
Effect Of Splenectomy ◽  
Maximal Induction ◽  
Metabolizing Enzyme ◽  
Cytochrome P 450 ◽  
Liver Microsomal Enzymes

Splenectomy was performed in adult female rats in order to investigate the influence of removal of the spleen on liver microsomal enzymes and cytochrome P-450 in vitro, as well as on the pharmacological activity of certain drugs in intact animals. Splenectomy significantly decreases the amount of cytochrome P-450 at 1 and 4 days after the operation, but not at 7 days. The activity of the enzymes catalyzing the metabolism of parathion, p-nitroanisole, and zoxazolamine is also decreased 4 days after splenectomy, whereas that of the enzymes involved in the metabolism of hexobarbital is unchanged. The maximal induction by phenobarbital of the enzymatic activities catalyzing the metabolism of parathion, p-nitroanisole, and zoxazolamine is prevented by splenectomy. Splenectomy exerts very little effect on plasma levels of hexobarbital and hexobarbital sleeping time; however, in both control and phenobarbital-pretreated rats, splenectomy results in a marked increase in the duration of zoxazolamine paralysis. These results indicate that splenectomy exerts inhibitory effects on certain liver microsomal enzymes, and provide some indirect evidence in support of the view that the hepatic blood supply is important for maintaining normal levels of drug-metabolizing enzyme activity in the liver.

scholarly journals Hepatic drug-metabolizing enzyme activity in rats pretreated with (−)-emetine or (±)-2,3-dehydroemetine

1970 ◽  
Vol 117 (3) ◽  
pp. 491-498 ◽  
Author(s):  
H. H. Miller ◽  
R. K. Johnson ◽  
J. D. Donahue ◽  
W. R. Jondorf
Keyword(s):  
Enzyme Activity ◽  
Female Rats ◽  
Inhibitory Effects ◽  
Hepatic Drug ◽  
Azo Reduction ◽  
Drug Metabolizing Enzyme ◽  
Metabolizing Enzyme ◽  
Sodium Phenobarbital ◽  
Stimulation Of

1. Pretreatment of female rats with (−)-emetine or (±)-2,3-dehydroemetine (at 18μmol/kg body wt. for 24h) prolongs the hexobarbital-induced sleeping-time of the treated animals. 2. This effect is not observed on pretreating animals with other compounds closely related to (−)-emetine, such as (−)-isoemetine or (+)-O-methylpsychotrine. 3. Liver microsomal drug-metabolizing enzyme activity in vitro as measured by N-demethylation of aminopyrine and azo-reduction of Neoprontosil is inhibited in rats pretreated with (−)-emetine or with (±)-2,3-dehydroemetine. 4. These inhibitory effects on drug metabolism in vitro are not observed in corresponding experiments involving pretreatment of rats with (−)-isoemetine or (+)-O-methylpsychotrine. 5. Co-administration of emetine or 2,3-dehydroemetine and sodium phenobarbital or 1,1-dichloro-2-o-chlorophenyl-2-p-chlorophenylethane to rats abolishes or greatly diminishes the stimulation of drug-metabolizing enzyme activity in vitro usually obtained by the administration of phenobarbital or 1,1-dichloro-2-o-chlorophenyl-2-p-chlorophenylethane alone. 6. Further, in rats pretreated with sodium phenobarbital and subsequently injected with emetine or 2,3-dehydroemetine the pre-stimulated drug-metabolizing enzyme activity in vitro is diminished. 7. The inhibitory effects on drug-metabolizing enzyme activity after pretreatment with (−)-emetine or (±)-2,3-dehydroemetine do not appear to be related to NADPH generation.

scholarly journals Triacylglycerol metabolism in the phenobarbital-treated rat

1981 ◽  
Vol 196 (1) ◽  
pp. 337-346 ◽  
Author(s):  
David M. Goldberg ◽  
M. Waheed Roomi ◽  
Alexander Yu ◽  
Daniel A. K. Roncari
Keyword(s):  
Enzyme Induction ◽  
Diacylglycerol Acyltransferase ◽  
Female Rats ◽  
Male Rats ◽  
Microsomal Enzyme ◽  
Triacylglycerol Metabolism ◽  
Triacylglycerol Content ◽  
Hepatic Triacylglycerol ◽  
Microsomal Enzyme Induction

1. Various aspects of triacylglycerol metabolism were compared in rats given phenobarbital at a dose of 100mg/kg body wt. per day by intraperitoneal injection; controls were injected with an equal volume of 0.15m-NaCl by the same route. Animals were killed after 5 days of treatment. 2. Rats injected with phenobarbital demonstrated increased liver weight, and increased microsomal protein per g of liver. Other evidence of microsomal enzyme induction was provided by increased activity of aminopyrine N-demethylase and cytochrome P-450 content. Increased hepatic activity of γ-glutamyltransferase (EC 2.3.2.2) occurred in male rats, but not in females, and was not accompanied by any detectable change in the activity of this enzyme in serum. 3. Phenobarbital treatment increased the hepatic content of triacylglycerol after 5 days in starved male and female rats, as well as in non-starved male rats; non-starved females were not tested in this regard. At 5 days after withdrawal of the drug, there was no difference in hepatic triacylglycerol content or in hepatic functions of microsomal enzyme induction between the treated and control rats. 4. After 5 days, phenobarbital increased the synthesis in vitro of glycerolipids in cell-free liver fractions fortified with optimal concentrations of substrates and co-substrates when results were expressed per whole liver. The drug caused a significant increment in the activity of hepatic diacylglycerol acyltransferase (EC 2.3.1.20), but did not affect the activity per liver of phosphatidate phosphohydrolase (EC 3.1.3.4) in cytosolic or washed microsomal fractions. A remarkable sex-dependent difference was observed for this latter enzyme. In female rats, the activity of the microsomal enzyme per liver was 10-fold greater than that of the cytosolic enzyme, whereas in males, the activities of phosphohydrolases per liver from both subcellular fractions were similar. 5. The phenobarbital-mediated increase in hepatic triacylglycerol content could not be explained by a decrease in the hepatic triacylglycerol secretion rate as measured by the Triton WR1339 technique. Since the hepatic triacylglycerol showed significant correlation with microsomal enzyme induction functions, with hepatic glycerolipid synthesis in vitro and with diacylglycerol acyltransferase activity, it is likely to be due to enhanced triacylglycerol synthesis consequent on hepatic microsomal enzyme induction. 6. In contrast with rabbits and guinea pigs, rats injected with phenobarbital showed a decrease in serum triacylglycerol concentration in the starved state; this decrease persisted for up to 5 days after drug administration stopped, and did not occur in non-starved animals. It seems to be independent of the microsomal enzyme-inducing properties of the drug, and may be due to the action of phenobarbital at an extrahepatic site.

scholarly journals Generation of tetracycline-controllable CYP3A4-expressing Caco-2 cells by the piggyBac transposon system

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Moe Ichikawa ◽  
Hiroki Akamine ◽  
Michika Murata ◽  
Sumito Ito ◽  
Kazuo Takayama ◽  
...  
Keyword(s):  
Small Intestine ◽  
Drug Absorption ◽  
Cell Model ◽  
Negative Effects ◽  
Piggybac Transposon ◽  
Drug Metabolizing Enzyme ◽  
Metabolizing Enzyme ◽  
Cyp3a4 Expression

AbstractCaco-2 cells are widely used as an in vitro intestinal epithelial cell model because they can form a monolayer and predict drug absorption with high accuracy. However, Caco-2 cells hardly express cytochrome P450 (CYP), a drug-metabolizing enzyme. It is known that CYP3A4 is the dominant drug-metabolizing enzyme in human small intestine. In this study, we generated CYP3A4-expressing Caco-2 (CYP3A4-Caco-2) cells and attempted to establish a model that can simultaneously evaluate drug absorption and metabolism. CYP3A4-Caco-2 cells were generated by piggyBac transposon vectors. A tetracycline-controllable CYP3A4 expression cassette (tet-on system) was stably transduced into Caco-2 cells, thus regulating the levels of CYP3A4 expression depending on the doxycycline concentration. The CYP3A4 expression levels in CYP3A4-Caco-2 cells cultured in the presence of doxycycline were similar to or higher than those of adult small intestine. The CYP3A4-Caco-2 cells had enough ability to metabolize midazolam, a substrate of CYP3A4. CYP3A4 overexpression had no negative effects on cell proliferation, barrier function, and P-glycoprotein activity in Caco-2 cells. Thus, we succeeded in establishing Caco-2 cells with CYP3A4 metabolizing activity comparable to in vivo human intestinal tissue. This cell line would be useful in pharmaceutical studies as a model that can simultaneously evaluate drug absorption and metabolism.

scholarly journals Effects of phenobarbital upon triacylglycerol metabolism in the rabbit

1980 ◽  
Vol 192 (1) ◽  
pp. 165-175 ◽  
Author(s):  
D M Goldberg ◽  
M W Roomi ◽  
A Yu ◽  
D A K Roncari
Keyword(s):  
Enzyme Induction ◽  
Microsomal Enzyme ◽  
Gamma Glutamyltransferase ◽  
Triacylglycerol Metabolism ◽  
Triacylglycerol Synthesis ◽  
Triacylglycerol Content ◽  
Phosphatidate Phosphohydrolase ◽  
Hepatic Triacylglycerol ◽  
Microsomal Enzyme Induction

1. The association between hepatic microsomal enzyme induction and triacylglycerol metabolism was examined in fasting male rabbits (2kg body wt.) injected intra-peritoneally with 50 mg of phenobarbital per kg for 10 days. 2. Occurrence of enzyme induction was established by a significant increase in hepatic aminopyrine N-demethylase activity and cytochrome P-450 content, as well as a doubling of microsomal protein per g of liver and a 54% increase in liver weight. Parallel increments in hepatic gamma-glutamyltransferase (EC 2.3.2.2) activity occurred; these were more pronounced in the whole homogenate than in the microsomes, which only accounted for 12.5% of the total enzyme activity in the controls and 17.0% in the animals given phenobarbital. Increased activity of gamma-glutamyltransferase activity was also observed in the blood serum of the test animals. 3. The rabbits given phenobarbital manifested increased hepatic triacylglycerol content and the triacylglycerol concentration of blood serum was also elevated. These changes were accompanied by a significantly enhanced ability of cell-free fractions of liver from the test animals (postmitochondrial supernatant and microsomal fractions) to synthesize glycerolipids in vitro from sn-[14C] glycerol 3-phosphate and fatty acids, when expressed per whole liver. Relative to the protein content of the fraction, glycerolipid synthesis in vitro was significantly decreased in the microsomes, presumably consequent upon the dramatic increase in their total protein content, whereas no change occurred in the postmitochondrial supernatant, possibly due to the protective effect of cytosolic factors present in this fraction and known to enhance glycerolipid synthesis. 4. Microsomal phosphatidate phosphohydrolase accounted for 85% of the total liver activity of this enzyme and its specific activity was 20-fold higher than that of the cytosolic phosphatidate phosphohydrolase (EC 3.1.3.4), when each was measured under optimal conditions. A significant increase in the activity of both enzymes per whole liver occurred in the rabbits given phenobarbital. A closer correlation between hepatic triacylglycerol content and and microsomal phosphatidate phosphohydrolase, as well as the above observation, suggest that this, rather than the cytosolic enzyme, may be rate-limiting for triacylglycerol synthesis in rabbit liver. 5. Significant correlations were observed between the various factors of hepatic microsomal-enzyme induction (aminopyrine N-demethylase and gamma-glutamyltransferase activity as well as cytochrome P-450 content) and hepatic triacylglycerol content, suggesting that that microsomal enzyme induction may promote hepatic triacylglycerol synthesis and consequently hypertriglyceridaemia in the rabbit.

A pharmacogenetic model predicting low paclitaxel clearance based on the DMET platform.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 2597-2597
Author(s):  
Annemieke J.M. Nieuweboer ◽  
Anne-Joy M. de Graan ◽  
Laure Elens ◽  
Marcel Smid ◽  
John W. M. Martens ◽  
...  
Keyword(s):  
Positive Predictive Value ◽  
Prediction Model ◽  
Predictive Value ◽  
Plasma Concentrations ◽  
Sampling Strategy ◽  
High Sensitivity ◽  
Cancer Drug ◽  
Drug Metabolizing Enzyme ◽  
Validation Set ◽  
Metabolizing Enzyme

2597 Background: Paclitaxel (PTX) is a commonly used cytotoxic agent. It is metabolized by P450 cytochrome iso-enzymes CYP3A4 and CYP2C8 and has high interindividual variability in pharmacokinetics (PK) and toxicity. Here, we present a genetic prediction model to identify patients with low PTX clearance (CL) using the new Drug-Metabolizing Enzyme and Transporter (DMET; Affymetrix) platform, capable of detecting 1,936 genetic variants (SNPs) in 225 genes. Methods: In a PK study, 270 Caucasian cancer patients were treated with PTX. PK parameters were determined using a limited sampling strategy. HPLC or LC-MS/MS were used to determine PTX plasma concentrations and non-linear mixed effects modelling (NONMEM) was used to estimate individual unbound CL from previously developed PK population models. Subsequently, the cohort of patients was randomly split into a training and validation set. In all patients, the presence of SNPs in metabolic enzymes and transporters was determined using the DMET platform. Selected SNPs were subsequently validated in the validation set. Results: Baseline characteristics were comparable in both sets. The mean CL of the total cohort was 488 ± 149 L/h and the threshold for low CL was set at 339 L/h (1 SD < total mean CL). 14 SNPs were selected to be included in the prediction model and validated in the validation set. For none of these 14 SNPs, evidence for a biological plausible link to taxane metabolism exists. The developed prediction model had a sensitivity of 95% to identify low PTX CL, a positive predictive value of 22% and remained significantly associated with low CL after multivariate analysis correcting for age, gender and Hb levels at start of therapy (P=0.024). Conclusions: This is the first considerably-sized application of the DMET platform to explain PK variability of a widely used anti-cancer drug. Although this validated prediction model for PTX CL had a high sensitivity, its positive predictive value is too low to be of direct clinical use. Likely, genetic variability in DMET genes alone does not sufficiently explain PTX CL, as for example environmental factors may also influence PTX metabolism.

Effect of acetaminophen on liver microsomal drug-metabolizing enzyme in vitro in mice

1977 ◽  
Vol 26 (9) ◽  
pp. 893-895 ◽  
Author(s):  
Aikawa Kazuo ◽  
Satoh Tetsuo ◽  
Kitagawa Haruo
Keyword(s):  
Drug Metabolizing Enzyme ◽  
Metabolizing Enzyme

scholarly journals FMO1 catalyzes the production of taurine from hypotaurine

2019 ◽  
Author(s):  
Sunil Veeravalli ◽  
Ian R. Phillips ◽  
Rafael T. Freire ◽  
Dorsa Varshavi ◽  
Jeremy R. Everett ◽  
...  
Keyword(s):  
De Novo ◽  
Cysteic Acid ◽  
Muscle Disorders ◽  
H Nmr ◽  
Drug Metabolizing Enzyme ◽  
Anti Oxidant ◽  
Metabolizing Enzyme ◽  
Skeletal Muscle Disorders

ABSTRACTTaurine is one of the most abundant amino acids in mammalian tissues. It is obtained from the diet and by de novo synthesis, from cysteic acid or hypotaurine. Despite the discovery in 1954 that the oxygenation of hypotaurine produces taurine, the identification of an enzyme catalyzing this reaction has remained elusive. In large part this is due to the incorrect assignment, in 1962, of the enzyme as a NAD-dependent hypotaurine dehydrogenase. For more than 55 years the literature has continued to refer to this enzyme as such. Here we show, both in vivo and in vitro, that the enzyme that oxygenates hypotaurine to produce taurine is flavin-containing monooxygenase 1 (FMO1). Metabolite analysis of the urine of Fmo1-null mice by 1H NMR spectroscopy revealed a build-up of hypotaurine and a deficit of taurine in comparison with the concentrations of these compounds in the urine of wild-type mice. In vitro assays confirmed that FMO1 of human catalyzes the conversion of hypotaurine to taurine utilizing either NADPH or NADH as co-factor. FMO1 has a wide substrate range and is best known as a xenobiotic- or drug-metabolizing enzyme. The identification that the endogenous molecule hypotaurine is a substrate for the FMO1-catalyzed production of taurine resolves a long-standing mystery. This finding should help establish the role FMO1 plays in a range of biological processes in which taurine or its deficiency is implicated, including conjugation of bile acids, neurotransmitter, anti-oxidant and anti-inflammatory functions, the pathogenesis of obesity and skeletal muscle disorders.

Sign in / Sign up

Export Citation Format

Share Document